BDTX · Black Diamond Therapeutics, Inc.
$2.21
+0.06 (+2.79%)
At close · Aug 21
Market Cap
$126.97M
Shares
57.45M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.21
Open$2.15
Day$2.15–2.26
52W close$1.61–4.87
Avg vol 30d664K
Short int5.9M · 10.2% float · 8.7d
Short vol53%
Last earningsDec 3, 2025
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
+19%
above
RSI (14)
67
neutral
MACD trend
Positive
52-week position
18%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+26%
trailing
6-month return
−9%
trailing
YTD return
−9%
this year
Relative strength
−21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.20% of float · ▲ +0.2% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
98 holders — mid 3-yr range
Squeeze score
74
high risk · 0–100
Fundamentals
EPS growth
+131%
Y/Y
Free cash flow
$29.6M
Balance sheet
$21.0M
net cash
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Cash, cash equivalents and investments (cash runway)
· into the second half of 2028
$118.3M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
+19%
Bullish
RSI (14)
67
Neutral
MACD trend
Positive
Bullish
52-week position
18%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.20% of float · ▲ +0.2% MoM · 8.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
98 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 18%
Range high $5
vs 200-day avg -12%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and investments | $110.5M | the second quarter of 2026 | — |
| CNS ORR (ORR by RANO-BM) | 86% | As of an April 11, 2026 data cutoff date | — |
| Disease Control Rate (DCR) | 91% | As of an April 11, 2026 data cutoff date | — |
| Longest duration on therapy | 23.5 | As of an April 11, 2026 data cutoff date | — |
| Median progression-free survival | 15.2 | As of an April 11, 2026 data cutoff date | — |
| Objective Response Rate (ORR by RECIST 1.1) | 60% | As of an April 11, 2026 data cutoff date | — |
| Patients remained on therapy | 23 | As of an April 11, 2026 data cutoff date | — |
| Patients with EGFRm NSCLC or EGFR-altered GBM treated with silevertinib | 200 | To date | — |
| Rate of treatment-related adverse events greater than or equal to Grade 3 | 28% | As of an April 11, 2026 data cutoff date | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BDTX
this stock
Black Diamond Therapeutics, Inc.
|
$126.97M | -9.1% | — | — | 10.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BDTX | +9.4% | +25.6% | -9.1% | +30.8% | -9.1% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +10.8% | +21.9% | -20.6% | +28.3% | -21.3% |
Key facts
CIK
1701541
CUSIP
09203E105
13F (30d)
92 filings
91 filers
Visit website
Investor relations